|Day Low/High||0.91 / 0.95|
|52 Wk Low/High||0.22 / 1.60|
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
An updated calendar listing FDA drug approval decisions and advisory panels for the remainder of 2012.
Adam Feuerstein, senior columnist for TheStreet, explains why Alexza Pharmaceuticals is the next big thing in biotech.
Alexza Pharmaceuticals (Nasdaq:ALXA) has been downgraded by TheStreet Ratings from from a hold to sell.
Shares of Alexza Pharmaceuticals (Nasdaq:ALXA) were gapping down Friday morning with an open price 31.4% lower than Thursday's closing price. The stock closed at 70 cents yesterday and opened today's trading at 48 cents.
Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
Shares of Alexza Pharmaceuticals (Nasdaq:ALXA) were gapping up Tuesday morning with an open price 14.5% higher than Friday's closing price. The stock closed at 83 cents yesterday and opened today's trading at 95 cents.
TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech stock investing.
Shares of Alexza Pharmaceuticals (Nasdaq:ALXA) have taken a tremendous swing upward. The stock is trading at 89 cents as of 10:10 a.m. ET, 42.5% above Monday's closing price of 62 cents. Volume is at 6.7 million, 11.9 times the daily average of 565,100.
An FDA panel is reviewing Alexza's Adasuve, which is seeking approval for treatment of agitation in schizophrenia patients.
Shares of Alexza Pharmaceuticals (Nasdaq:ALXA) have taken a tremendous swing upward. The stock is trading at 63 cents as of 1:20 p.m. ET, 21.1% above Thursday's closing price of 52 cents. Volume is at 2.2 million, 5.6 times the daily average of 402,600.
These are the biotech and drug stocks facing key FDA drug approval decisions in 2012.
Alexza Pharmaceuticals (Nasdaq:ALXA) has been upgraded by TheStreet Ratings from a sell to hold.
An updated list of drug and biotech firms with drug approvals expected through the first quarter 2012.
Here's a list of August's potentially stock-moving biotech events.
Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.
Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Oct 15, 2010.
Meet the five contestants with perfect 5-0 records so far in TheStreet's FDA Drug-Approval Contest
Painkillers are in the biotech spotlight Tuesday, as King Pharmaceuticals sells itself to Pfizer and tiny pain medicine developer Pain Therapeutics benefits by extension.
Analyst sentiment is very strong for most of these highly-rated Big Pharma plays.
Alexza shares crash Monday after the FDA denies approval of a key drug, but Geron gains as the company begins a historic stem-cell study.
Guests include Michael D'Antonio, author "Spend Shift", Joseph Berwind, author of "Investing in Solar Stocks", Stephanie Link, director of research Action Alerts Plus
U.S. regulators have issued four drug approval decisions this month and all have been rejections.
FDA refuses to approve Alexza's drug-device AZ-004 for schizophrenia, citing lung safety concerns.
Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Oct. 8, 2010.
FDA will approve drugs by Alkermes and Amylin but will turn away Arena and Vivus, according to reader predictions in TheStreet's FDA Drug-Approval Contest
Try to correctly predict the approval decisions made by the U.S. Food and Drug Administration on 11 new drugs in October.
Here's a list of October's potentially stock-moving biotech events.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.